The device makes use of image guidance and precise, targeted needle placement. Credit: Peter Porrini / Shutterstock.

The US Food and Drug Administration (FDA) has awarded breakthrough device designation for Obvius Robotics’ Certa Access System for central venous catheterisation (CVC).

The hand-held image-guided percutaneous access device aims to standardise and improve the outcomes of these procedures.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Certa is not yet approved for clinical use. Obvius Robotics is actively preparing for its FDA market clearance submission.

Obvius Robotics chief medical officer William Cohn said: “CVC procedures are required for a wide variety of conditions and patients for life-saving care every single day.

“Despite this fact, the procedure still has high complication rates and many health systems lack the expertise to reliably conduct the procedure on critically ill patients in a timely manner. A breakthrough is truly needed to improve care.”

See Also:

The device makes use of image guidance and precise, targeted needle placement, enabling clinicians to identify target structures such as blood vessels, and rapidly gain access for CVC placement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Obvius Robotics president and CEO Russell Seiber said: “The goal of Obvius Robotics is to become the new standard of care for CVC access.

“We are excited that the FDA has recognised the potential of the CERTA Access System to be a breakthrough for patients and clinicians. We believe this technology could improve care critical care settings by democratising vascular access procedures.”

In June 2023, Obvius Robotics completed the first in-human study using its CERTA Access System.

The device combines robotics and imaging, allowing clinicians to single-handedly target and access anatomical structures using a targeting system and needle assembly.